Welcome to our dedicated page for Cochlear Ord Adr news (Ticker: CHEOY), a resource for investors and traders seeking the latest updates and insights on Cochlear Ord Adr stock.
The CHEOY news page aggregates coverage related to Cochlear plc Unsponsored ADR and the underlying company, Cochlear Limited (ASX: COH), which describes itself as the global leader in implantable hearing solutions. Here you can read about product launches, technology milestones, collaborations and recognition that shape the company’s role in hearing healthcare.
Recent news has featured the Cochlear Nucleus Nexa System, described by the company as the world’s first and only smart cochlear implant system with upgradeable implant firmware and internal memory in the implant. Other announcements highlight the Baha 7 Sound Processor and Baha SoundBand for bone conduction hearing, as well as the Osia System with the OSI300 Implant, which Cochlear reports is the first active bone conduction system to enable MRI at 3.0 Tesla without surgery.
Beyond product updates, Cochlear’s releases cover topics such as scholarship awards for Nucleus, Baha and Osia recipients in the United States and Canada, recognition in Newsweek rankings as the most trustworthy healthcare company, and partnerships like a multi-year research collaboration with Google and Australian Hearing Hub members to explore machine learning and other methods for hearing technologies.
Investors and observers following CHEOY can use this news feed to track how Cochlear presents its technology roadmap, clinical and policy engagement around hearing loss, and initiatives in customer support, such as visual assistance using augmented reality. Bookmark this page to review ongoing announcements that reflect the company’s activities in implantable hearing solutions and hearing health advocacy.
Cochlear welcomes the WHO's first World Report on Hearing, launched on March 3, 2021, which calls for prioritizing hearing health globally. The report highlights that 1.5 billion people experience some degree of hearing loss, with around 60 million facing severe to complete loss. It emphasizes the effectiveness and cost-effectiveness of cochlear implants and urges member states to integrate hearing care into primary health systems. Cochlear's CEO, Dig Howitt, stresses the need for urgent action to tackle the rising prevalence of hearing loss, supported by prominent advocates like Malala Yousafzai.
Cochlear Limited (ASX: COH) announced the winners of the 2021 Graeme Clark and Anders Tjellström Scholarships, recognizing eight exemplary Cochlear™ Nucleus® Implant, Baha® System, and Osia® System recipients from the U.S. and Canada. Each winner will receive $2,000 per year for up to four years, totaling $64,000 in scholarships for this year alone. Since 2002, the company has awarded $824,000 to 112 students. The scholarships aim to support Cochlear recipients in achieving their educational and career goals while promoting leadership in the hearing loss community.
Cochlear Limited (ASX: COH) launched the Hearing 20/20 campaign during Audiology Awareness Month to promote a common metric for normal hearing: 20 decibels in each ear. Supported by ten partners, this initiative aims to emphasize the significance of hearing health, especially for adults aged 55 and older. The campaign highlights that the third most common chronic condition, hearing loss, impacts many, yet only 9% of consumers know its definition. Cochlear encourages annual hearing tests and discussions regarding hearing health with primary care providers.
Cochlear Limited (ASX: COH) has introduced the Cochlear Hearing Aid Check, a new online tool aimed at helping adults with hearing loss determine if they could benefit from a cochlear implant. During Healthy Aging Month, this free tool provides comparative insights between hearing aids and cochlear implants. Notably, research indicates that a significant portion of adults over 50 years old perform poorly with hearing aids. With an increasing prevalence of hearing loss among older adults, this initiative aims to improve awareness and access to effective solutions like cochlear implants.